<DOC>
	<DOCNO>NCT01356342</DOCNO>
	<brief_summary>This open study use AdimFlu-S ( 2010-2011 season ) vaccine young subject age 6 month old 18 year old . All participant divide three age cohort . First , participant age 6 &lt; 36 month receive 2 dos 0.25 mL vaccine separate 4 week . Second , participant age 3 &lt; 9 year receive 2 dos 0.5 mL vaccine separate 4 week . Third , participant age 9 &lt; 18 year receive one dose 0.5 mL vaccine . Safety outcomes include immediate reaction time vaccination , solicit local systemic reaction within 7 day vaccination , unsolicited adverse event , serious adverse event . Sera prepare blood sample collect subject immediately prior , 4 week vaccination . Anti-hemaglutinin ( HA ) antibody titer determine use WHO haemaglutination inhibition reference technique . The analysis observer-blinded . All participant follow , either clinical visit telephone contact , 6 month first vaccination safety reason .</brief_summary>
	<brief_title>Immunogenicity Safety Trivalent Inactivated Influenza Vaccine , Formulation 2010-2011 , Healthy Subjects Aged Over 6 Months Old 18 Years Old</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Boys girl age 6 month old 18 year old day first vaccination ; Subject and/or parent ( ) /legal guardian ( ) must willing comply plan study procedure available study visit ; Subject must good physical health basis medical history , physical examination ; Subject and/or parent ( ) /legal guardian ( ) must read sign studyspecific inform consent prior initiation study procedure . Subjects received influenza vaccine ( Trivalent and/or A ( H1N1 ) ) within previous 6 month ; History hypersensitivity egg egg protein similar pharmacological effect study medication ; Personal family history GuillainBarré Syndrome ; An acute febrile illness within 1 week prior vaccination ; Current upper respiratory illness ( URI ) , include common cold nasal congestion within 72 hour ; Subjects influenzalike illness define presence fever ( temperature ³38ºC ) least two follow four symptom : headache , muscle/joint ache pain ( e.g . myalgia/arthralgia ) , sore throat cough ; Female subject pregnant , lactate likely become pregnant study ; Women childbearing potential disagree use acceptable method contraception ( e.g. , hormonal contraceptive , IUD , barrier device abstinence ) throughout study ; Treatment investigational drug device , participation clinical study , within 3 month consent ; Immunodeficiency , immunosuppressive household contact immunosuppression ; History wheeze bronchodilator use within 3 month prior study vaccine ; Receipt live virus vaccine within 1 month prior study vaccine expect receipt vaccination last blood sample immunogenicity evaluation ; Receipt inactivate vaccine within 2 week prior study vaccination expect receipt vaccination last blood sample immunogenicity evaluation ; Receipt blood product , include immunoglobulin prior 3 month ; Underlying condition investigator ' opinion may interfere evaluation vaccine ; Significant chronic illness inactivate influenza vaccine recommend commonly use .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>